The immunogenicity of humanized and fully human antibodies

References

• Wagner KS, Stickings P, White JM, Neal S, Crowcroft NS, Sesardic D, et al. A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. Vaccine 2009; 28:14 - 20
   PubMed Web of Science ®Google Scholar
• Silverstein AM. Clemens Freiherr von Pirquet: explaining immune complex disease in 1906. Nat Immunol 2000; 1:453 - 455
   PubMed Web of Science ®Google Scholar
• Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 1995; 105:23 - 29
   PubMed Web of Science ®Google Scholar
• Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 2005; 36:69 - 83
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3 - 10
   PubMed Web of Science ®Google Scholar
• Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20:450 - 459
   PubMed Web of Science ®Google Scholar
• Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117 - 1125
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105 - 1116
   PubMed Web of Science ®Google Scholar
• Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231:11 - 23
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41:82 - 88
   PubMed Web of Science ®Google Scholar
• Lusher JM. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica 2000; 85:2 - 5
   PubMedGoogle Scholar
• Rup B. Immunogenicity and immune tolerance coagulation Factors VIII and IX. Dev Biol (Basel) 2003; 112:55 - 59
   PubMedGoogle Scholar
• Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001; 61:6851 - 6859
   PubMed Web of Science ®Google Scholar
• Welt S, Ritter G, Williams C Jr, Cohen LS, Jungbluth A, Richards EA, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003; 9:1347 - 1353
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 2003; 112:15 - 21
   PubMedGoogle Scholar
• de Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008; 8:620 - 626
   PubMed Web of Science ®Google Scholar
• Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008; 14:191 - 202
   PubMedGoogle Scholar
• Holgate RG, Baker MP. Circumventing immunogenicity in the development of therapeutic antibodies. IDrugs 2009; 12:233 - 237
   PubMed Web of Science ®Google Scholar
• Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009; 20:708 - 714
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. Aaps J 2006; 8:501 - 507
   PubMed Web of Science ®Google Scholar
• Hendrickson JE, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, Roback JD, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 2006; 46:1526 - 1536
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49:697 - 702
   PubMed Web of Science ®Google Scholar
• Belmar NA, Lombardo JR, Chao DT, Li O, Ma X, Pong-Afar M, et al. Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. J Neuroimmunol 2009; 212:65 - 73
   PubMed Web of Science ®Google Scholar
• Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 2008; 152:138 - 146
   PubMed Web of Science ®Google Scholar
• Garman RD, Munroe K, Richards SM. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol 2004; 137:496 - 502
   PubMed Web of Science ®Google Scholar
• Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:73 - 77
   Google Scholar
• Gogolak P, Rethi B, Hajas G, Rajnavolgyi E. Targeting dendritic cells for priming cellular immune responses. J Mol Recognit 2003; 16:299 - 317
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21 - 50
   PubMed Web of Science ®Google Scholar
• Sheeley DM, Merrill BM, Taylor LC. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. Anal Biochem 1997; 247:102 - 110
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109 - 1117
   PubMed Web of Science ®Google Scholar
• Eggleton P, Haigh R, Winyard PG. Consequence of neo-antigenicity of the ‘altered self’. Rheumatology 2008; 47:567 - 571
   PubMed Web of Science ®Google Scholar
• Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity 2007; 40:131 - 137
   PubMed Web of Science ®Google Scholar
• Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007; 10:219 - 227
   PubMed Web of Science ®Google Scholar
• Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 2004; 9:82 - 90
   PubMed Web of Science ®Google Scholar
• Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5:172 - 179
   PubMedGoogle Scholar
• Tangri S, LiCalsi C, Sidney J, Sette A. Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem 2002; 9:2191 - 2199
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5:853 - 865
   PubMed Web of Science ®Google Scholar
• Miller MJ, Safrina O, Parker I, Cahalan MD. Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med 2004; 200:847 - 856
   PubMedGoogle Scholar
• Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, et al. In vivo activation of antigen-specific cd4 t cells. Annu Rev Immunol 2001; 19:23 - 45
   PubMed Web of Science ®Google Scholar
• Bogen B, Ruffini P. Review: to what extent are T cells tolerant to immunoglobulin variable regions?. Scand J Immunol 2009; 70:526 - 530
   PubMed Web of Science ®Google Scholar
• Ostad M, Andersson M, Gruber A, Sundblad A. Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. Blood 2008; 111:2725 - 2732
   PubMed Web of Science ®Google Scholar
• Munthe LA, Os A, Zangani M, Bogen B. MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol 2004; 172:7476 - 7484
   PubMed Web of Science ®Google Scholar
• Munthe LA, Corthay A, Os A, Zangani M, Bogen B. Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol 2005; 175:2391 - 2400
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2009; 23:137 - 142
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327:1209 - 1215
   PubMed Web of Science ®Google Scholar
• Eyerman MC, Zhang X, Wysocki LJ. T cell recognition and tolerance of antibody diversity. J Immunol 1996; 157:1037 - 1046
   PubMed Web of Science ®Google Scholar
• Guo W, Smith D, Guth A, Aviszus K, Wysocki LJ. T cell tolerance to germline-encoded antibody sequences in a lupus-prone mouse. J Immunol 2005; 175:2184 - 2190
   PubMed Web of Science ®Google Scholar
• Boyton RJ, Altmann DM. Is selection for TCR affinity a factor in cytokine polarization?. Trends Immunol 2002; 23:526 - 529
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer-Williams MG. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 2009; 21:266 - 273
   PubMed Web of Science ®Google Scholar
• Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30:646 - 655
   PubMed Web of Science ®Google Scholar
• Locksley RM. Nine lives: plasticity among T helper cell subsets. J Exp Med 2009; 206:1643 - 1646
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Mortari F, Shiokawa S, Kirkham PM, Elgavish RA, Bertrand FE 3rd. Developmental regulation of the human antibody repertoire. Ann N Y Acad Sci 1995; 764:242 - 260
   PubMed Web of Science ®Google Scholar
• Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9:833 - 844
   PubMed Web of Science ®Google Scholar
• Dembic Z, Weiss S, Bogen B. Thymic selection of immunoglobulin idiotype specific T-cells. Thymus 1994; 22:141 - 152
   PubMedGoogle Scholar
• Parish IA, Heath WR. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol Cell Biol 2008; 86:146 - 152
   PubMedGoogle Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523 - 532
   PubMed Web of Science ®Google Scholar
• Ferry H, Leung JC, Lewis G, Nijnik A, Silver K, Lambe T, et al. B-cell tolerance. Transplantation 2006; 81:308 - 315
   PubMed Web of Science ®Google Scholar
• Hertz M, Nemazee D. Receptor editing and commitment in B lymphocytes. Curr Opin Immunol 1998; 10:208 - 213
   PubMed Web of Science ®Google Scholar
• Nussenzweig MC. Immune receptor editing: revise and select. Cell 1998; 95:875 - 878
   PubMed Web of Science ®Google Scholar
• Gilles JG, Vanzieleghem B, Saint-Remy JM. Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes. Semin Thromb Hemost 2000; 26:151 - 155
   PubMed Web of Science ®Google Scholar
• Pan ZJ, Anderson CJ, Stafford HA. Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest 1998; 102:215 - 222
   PubMed Web of Science ®Google Scholar
• Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci USA 2008; 105:5471 - 5476
   PubMed Web of Science ®Google Scholar
• Kenderov A, Minkova V, Mihailova D, Giltiay N, Kyurkchiev S, Kehayov I, et al. Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies. Clin Exp Immunol 2002; 129:169 - 176
   PubMed Web of Science ®Google Scholar
• Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19:857 - 865
   PubMed Web of Science ®Google Scholar
• Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002; 23:1 - 8
   PubMed Web of Science ®Google Scholar
• Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol 2007; 95:83 - 110
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125:373 - 389
   Google Scholar
• Hebert J, Bernier D, Boutin Y, Jobin M, Mourad W. Generation of anti-idiotypic and anti-anti-idiotypic monoclonal antibodies in the same fusion. Support of Jerne’s Network Theory. J Immunol 1990; 144:4256 - 4261
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BA, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006; 65:1249 - 1250
   PubMed Web of Science ®Google Scholar
• Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 2003; 112:37 - 53
   Google Scholar
• Mahler SM, Marquis CP, Brown G, Roberts A, Hoogenboom HR. Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNFalpha monoclonal antibodies. Immunotechnology 1997; 3:31 - 43
   PubMedGoogle Scholar
• Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368:856 - 859
   PubMed Web of Science ®Google Scholar
• Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134 - 1143
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2008;
   Web of Science ®Google Scholar
• Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27:269 - 274
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 2008; 28:1122 - 1126
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402 - 3412
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:964 - 975
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19:92 - 98
   PubMed Web of Science ®Google Scholar
• Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 2007; 178:7467 - 7472
   PubMed Web of Science ®Google Scholar
• Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2009; 39:321 - 326
   PubMed Web of Science ®Google Scholar
• Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, et al. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 2005; 4:1791 - 1800
   PubMed Web of Science ®Google Scholar
• Stickler M, Valdes AM, Gebel W, Razo OJ, Faravashi N, Chin R, et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4+ T-cell epitope in human interferon-beta. Genes Immun 2004; 5:1 - 7
   PubMed Web of Science ®Google Scholar
• Stickler M, Chin R, Faravashi N, Gebel W, Razo OJ, Rochanayon N, et al. Human population-based identification of CD4(+) T-cell peptide epitope determinants. J Immunol Methods 2003; 281:95 - 108
   PubMed Web of Science ®Google Scholar
• Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 2006; 24:541 - 570
   PubMed Web of Science ®Google Scholar
• Chowdhury D, Sen R. Regulation of immunoglobulin heavy-chain gene rearrangements. Immunol Rev 2004; 200:182 - 196
   PubMed Web of Science ®Google Scholar
• Wen YJ, Lim SH. Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma. Scand J Immunol 1999; 50:296 - 301
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139:2825 - 2833
   PubMed Web of Science ®Google Scholar
• Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest 2004; 113:1498 - 1510
   PubMed Web of Science ®Google Scholar
• Guo HH, Choe J, Loeb LA. Protein tolerance to random amino acid change. Proc Natl Acad Sci USA 2004; 101:9205 - 9210
   PubMed Web of Science ®Google Scholar
• Stickler MM, Estell DA, Harding FA. CD4+ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells. J Immunother 2000; 23:654 - 660
   PubMed Web of Science ®Google Scholar